Antimicrobial Agents and Chemotherapy · 2002 · 121 citations · 31 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial ResistanceAntibiotic ResistanceAntimicrobial Susceptibility TestingBacterial EpidemiologyBacterial InfectionsBeta-lactam ResistanceBeta-lactamase GenesEscherichia ColiExtended-spectrum Beta-lactamase Producing OrganismsExtended-spectrum Beta-lactamase ProductionExtended-spectrum Beta-lactamase-producing OrganismsExtended-spectrum Beta-lactamasesKlebsiella Pneumoniae ResistanceResistance In Clinical Isolates
Among 730 Escherichia coli, 438 Klebsiella pneumoniae, and 141 Proteus mirabilis isolates obtained between September 2000 and September 2001 in seven hospitals in Ho Chi Minh City, Vietnam, 26.6% were resistant to ceftazidime, 30% were resistant to cefotaxime, 31.5% were resistant to ceftriaxone, 15.9% were resistant to cefoperazone, and 6% were resistant to cefepime. Resistance to imipenem was found in 5.6% of the isolates. In 55 strains producing extended-spectrum beta-lactamases (32 E. coli isolates, 13 K. pneumoniae isolates, and 10 P. mirabilis isolates), structural genes for VEB-1 (25.5%), CTX-M (25.5%), SHV (38.1%), and TEM (76.3%) enzymes were detected alone or in combination. Sequencing of the PCR products obtained from the K. pneumoniae isolates revealed the presence of bla(VEB-1), bla(CTX-M-14), bla(CTX-M-17), bla(SHV-2), and bla(TEM-1). Molecular typing of the strains with a similar resistance phenotype to broad-spectrum cephalosporins indicated polyclonal spread. ISEcp1 was presumably responsible for dissemination of the bla(CTX-M-like) gene.
31
Vincent Jarlier, M. H. Nicolas, G. Fournier et al. · Clinical Infectious Diseases · 1988 · 1.6K citations